Ardelyx touts a PhIII hyperphosphatemia success for tenapanor, looking to calm fears over diarrhea
Ardelyx has been on a years-long roller coaster ride with their drug tenapanor. But early this morning the biotech $ARDX pulled the wraps off a Phase III study that they say met the primary endpoint for treating hyperphosphatemia in patients with end-stage renal disease who were on dialysis. And they add that they were able to do it with an acceptable level of problems with diarrhea — an issue that earlier raised an alarming warning flag for investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.